Related Experiment Video
Updated: Feb 16, 2026

07:27
Olfactory Assays for Mouse Models of Neurodegenerative Disease
Published on: August 25, 2014
22.7K
Non-Clinical Models for Neurodegenerative Diseases: Therapeutic Approach and Drug Validation in Animal Models
Caridad Ivette Fernandez1, Jessica López2, Lázara Martinez3
1Basic Division, International Center of Neurological Restoration (CIREN), Havana 11300, Cuba.
Behavioral Sciences (Basel, Switzerland)
|January 5, 2018
Summary
Cuba
Area of Science:
- Biomedical Sciences
- Neuroscience
- Gerontology
Background:
- Cuba's aging population (19.8% over 60 in 2016) necessitates focus on age-associated diseases.
- Neurodegenerative diseases are a growing public health concern, requiring advanced research.
- The Cuban biomedical community is actively pursuing research to address these challenges.
Purpose of the Study:
- To review the state-of-the-art in non-clinical models for neurodegenerative diseases.
- To foster collaboration and identify unifying objectives among international researchers.
- To explore new biotechnological products for diagnosis, therapy, and neuroprotection.
Main Methods:
- International congress on non-clinical models for neurodegenerative diseases.
- Review of current research trends in neurodegeneration.
- Discussion on the ethical and rational use of laboratory animals in research.
Main Results:
- Identified key areas for advancement in neurodegenerative disease research.
- Highlighted the importance of international collaboration and knowledge exchange.
- Emphasized the role of non-clinical models in developing diagnostic and therapeutic strategies.
Conclusions:
- Continued research and international collaboration are vital for combating neurodegenerative diseases.
- Development of novel biotechnological products is crucial for improved patient outcomes.
- Ethical and rational use of animal models remains essential for scientific progress in this field.
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Physiological Models
296
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
296
Model Approaches for Pharmacokinetic Data: Compartment Models
601
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Two primary types of compartment models are recognized: mammillary and catenary. The more...
601
Antipsychotic Drugs: Therapeutic Uses and Side Effects
864
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
864
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
268
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
268
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
18
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
18
Pharmacodynamic Models: Emax Drug–Concentration Effect Model
34
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
34

